Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications

Canadian Journal of Psychiatry

Volumn 51, Issue 8, 2006, Pages 502-511

  Faulkner, Guy ^a   Cohn, Tony A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotic medication; Intervention; Metabolic disturbance; Review; Schizophrenia; Weight management

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; CARBAMAZEPINE; CLOZAPINE; DEXFENFLURAMINE; FAMOTIDINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; DIET; DRUG EFFECT; EXERCISE; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HUMAN; META ANALYSIS; METABOLIC ACIDOSIS; METABOLIC DISORDER; NEPHROLITHIASIS; OBESITY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33746738880     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370605100805     Document Type: Review

References (56)

1. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93.
2. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006;51:492-501).
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, and others. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
4. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, and others. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43.
5. Muller DJ, Muglia P, Fortune T, Kennedy JL. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004;49:309-29.
6. Perry PJ, Argo TR, Carnahan RM, Lund BC, Holman TL, Ellingrod VL, and others. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 2005;25:250-4.
7. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004;65:766-71.
8. de Haan L, van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl) 2004;175:389-90.
9. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61(Suppl 11):37-41.
10. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003;64(Suppl 8):22-9.
11. Haupt DW, Flavio KS, Hessler MJ, Schweiger JA, Luber A, Fahnestock PA, and others. Effects of divalproex/antipsychotic polypharmacy of schizophrenia on adiposity and fasting lipids. Schizophr Bull 2005;31:563.
12. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, and others. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
13. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005;27:1930-41.
14. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23:595-600.
15. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64:580-8.
16. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004;71:195-212.
17. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, and others. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.
18. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003:CD004094.
19. Faulkner G, Cohn T, Remington G. Interventions for weight gain in schizophrenia. Protocol for a Cochrane Review. In: The Cochrane Library. Oxford (UK): Update Software; 2005.
20. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 2003;18:457-61.
21. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol 2004;19:37-40.
22. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:81-5.
23. Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004;14:332-6.
24. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, and others. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002;159:1058-60.
25. Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, and others. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 2003;28:527-9.
26. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, and others. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160:297-302.
27. Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, and others. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005;15:13-21.
28. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, and others. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954-62.
29. Weiden P, Radulovic L, Wang C, Allison D. Sibutramine for the treatment of obesity in schizophrenia: randomized, placebo controlled pilot study. Presented at the American Psychiatric Association Annual Meeting; 2003; San Francisco (CA).
30. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005;28:169-75.
31. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-7.
32. Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, and others. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006;51:192-6.
33. Cox SL. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. Drugs Today (Barc) 2005;41:499-508.
34. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, and others. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
35. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the stop-niddm randomised trial. Lancet 2002;359:2072-7.
36. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (xendos) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
37. Stone NJ, Saxon D. Approach to treatment of the patient with metabolic syndrome: Lifestyle therapy. Am J Cardiol 2005;96(4A):15E-21E.
38. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Schmid CH and others. Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review. Am J Prev Med 2005;28:126-39.
39. Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2005;28:2780-6.
40. Department of Health. At least five a week. A report from the chief medical officer. London (UK): HMSO; 2004. DoH, 2004.
41. Shaw K, O'Rourke P, Del Mar C, Kenardy J. Psychological interventions for overweight or obesity. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003818.
42. Jakicic JM, Clark K, Coleman E, Donnelly JE, Foreyt J, Melanson E, and others. American college of sports medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2001;33:2145-56.
43. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003;108:324-32.
44. Werneke U, Taylor D, Sanders TA, Wessely S. Behavioural management of antipsychotic-induced weight gain: a review. Acta Psychiatr Scand 2003;108:252-9.
45. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 2006;18:23-31.
46. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003;35:237-41.
47. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66:205-12.
48. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry 2005;39:479-86.
49. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 2006;95-101.
50. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21.
51. Le Fevre PD. Improving the physical health of patients with schizophrenia: Therapeutic nihilism or realism? Scott Med J 2001;46:11-3.
52. Richardson CR, Faulkner G, McDevitt J, Skrinar GS, Hutchinson DS, Piette JD. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv 2005;56:324-31.
53. Sallis JF, Owen N. Ecological models of health behaviour. In: Glanz K, Rimer B, Lewis F, editors. Health behaviour and health education: theory, research and practice. 3rd ed. San Francisco (CA): Jossey-Bass; 2002. p 462-84.
54. Gough S, Peveler R. Diabetes and its prevention: Pragmatic solutions for people with schizophrenia. Br J Psychiatry Suppl 2004;47:S106-11.
55. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988;153:208-13.
56. Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 2002;63:345-8.